Copyright
©The Author(s) 2022.
World J Transplant. Oct 18, 2022; 12(10): 313-324
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.313
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.313
Table 1 Clinical and demographic characteristics of kidney transplant recipients
| Characteristics | |
| Age, yr, median (range) | 46 (13-70) |
| Male/female | 49/22 |
| Living kidney donor | 22.5% |
| Deceased kidney donor | 77.5% |
| Previous kidney transplant | 7.0% |
| Preemptive transplantation | 4.2% |
| PRA(-) | 60.5% |
| Early rejection, within first 6 mo after KT | 4.2% |
| Induction therapy | |
| Basiliximab | 84.5% |
| ATG | 15.5% |
| Maintenance immune suppression | |
| Tacrolimus/mycophenolate/prednisone | 100.0% |
| Other | 0.0% |
| Distribution of underlying kidney disease | |
| Polycystic kidney disease | 22.5% |
| Primary glomerulopathies | 21.1% |
| Reflux nephropathy | 12.6% |
| Diabetes mellitus | 4.2% |
| Nephrosclerosis/hypertension | 4.2% |
| Urinary tract infections/ stones | 3.7% |
| Other | 16.2% |
| Unknown | 15.5% |
Table 2 Differences between panel reactive antibodies (-) and (+) patients
| Parameter | T0 (at renal transplantation) | ||
| PRA(-) | PRA(+) | P value | |
| Age, yr | 45 (13-65) | 47 (14-70) | NS |
| HDV, mo | 82.5 (0-251) | 112 (0-165) | NS |
| Time of cold ischemia, h | 18 (0-30) | 16.5 (0-30.5) | NS |
| Pre-emptive RT, % | 6 (13.6) | 1 (3.6) | NS |
| Acute rejection episode, % | 2 (4.5) | 1 (3.6) | NS |
| ATG administration, % | 5 (11.4) | 7 (25) | NS |
| DGF, % | 7 (15.9) | 4 (14.3) | NS |
Table 3 Lymphocyte numbers and subpopulations in panel reactive antibodies (-) and (+) patients at time of transplantation (T0)
| Parameter | T0, at renal transplantation | ||
| All patients | PRA(-) | PRA(+) | |
| n | 71 | 43 | 28 |
| Lymphocyte, % | 18.1 (6.4-40) | 18.8 (6.4-38.4) | 17.8 (11.2-40) |
| Lymphocyte, cells/μL | 1200 (700-2800) | 1200 (700-2800) | 1100 (700-2600) |
| CD4+, % | 42.0 (20.6-68.6) | 44.4 (20.6-68.6) | 41.5 (25.3-59.5) |
| CD4+, cells/μL | 515 (206-1453.2) | 557 (206-1453.2) | 435 (253-1362.4) |
| CD8+, % | 24.55 (10.5-53.1) | 25.1 (12,2-37.7) | 23.4 (10.5-53.1) |
| CD8+, cells/μL | 301.5 (91.7-665.6) | 301.5 (102.9-641.7) | 294.9 (91.7-665.6) |
| CD4+/CD8+ | 1.7 (0.6-5.6) | 1.5 (0.9-5.6) | 2 (0.6-5) |
| CD4+CD28-, % | 5.4 (0.0-33.7) | 4.8 (0.2-33.7) | 7.2 (0-32.1) |
| CD4+CD28-, cells/μL | 26.9 (0.0-206) | 26.7 (0-160) | 27.3 (0-206) |
| CD8+CD28-, % | 38.6 (6.1-91.5) | 38.3 (6.1-68.2) | 48.4 (15.1-91.5) |
| CD8+CD28-, cells/μL | 121.5 (13-583) | 113.6 (17-315) | 122 (13-583) |
| CD16/56, % | 18 (3.6-50.6) | 17.7 (3.6-50.6) | 18.4 (4.4-34.2) |
| CD16/56, cells/μL | 198.1 (50.4-750.5) | 210 (50.4-750.5) | 190.4 (94.8-393.6) |
| Tregs, %, on CD4 | 4 (0.1-11.5) | 3.9 (0.1-11.5) | 4.2 (1.5-7.3) |
| Tregs, cells/μL | 20 (0.52-74.38) | 20.2 (0.5-74.3) | 18.9 (5.8-73.5) |
Table 4 Changes in T lymphocyte subpopulations at T0, T3, and T6 time points in patients with panel reactive antibodies (-)
| Parameter | T0 | T3 | T6 | P value |
| Lymphocyte, % | 18.8 (6.4-38.4) | 23 (10.9-47.9) | 25.4 (8.4-52) | 0.001 |
| Lymphocyte, cells/μL | 1200 (700-2800) | 1650 (700-4100) | 1900 (800-3700) | < 0.0001 |
| CD4+, % | 44.4 (20.6-68.6) | 49.8 (22.7-77.1) | 49.1 (16.2-71.4) | 0.004 |
| CD4+, cells/μL | 557 (206-1453.2) | 782 (261.8-1951.6) | 872 (330-2001.6) | < 0.0001 |
| CD8+, % | 25.1 (12.2-37.7) | 26.9 (12.4-50.1) | 27.4 (13.3-49) | NS |
| CD8+, cells/μL | 301.5 (102.9-641.7) | 456.3 (148.6-1402.8) | 514.5 (189.2-1397.8) | < 0.0001 |
| CD4CD28null, % | 4.8 (0.2-33.7) | 2.8 (0-21.1) | 2.7 (0.1-36.4) | NS |
| CD4CD28null, cells/μL | 26.7 (0.9-149) | 27.5 (0-160) | 26.5 (09-241) | NS |
| CD8CD28null, % | 38.3 (6.1-68.2) | 28.4 (8.3-80.5) | 32.8 (6.7-90.7) | NS |
| CD8CD28null, cells/μL | 113.6 (17-315) | 112.6 (28-1129) | 158 (18-1267) | NS |
| CD16/56, % | 17.7 (3.6-50.6) | 6.6 (1.9-24.2) | 9.3 (2.9-28.6) | < 0.0001 |
| CD16/56, cells/μL | 210 (50.4-750.5) | 121.6 (33-622.2) | 151.2 (44-774.4) | < 0.0001 |
| Tregs, %, on CD4 | 3.9 (0.1-11.5) | 3.3 (0.9-6.8) | 4.1 (1.4-8.8) | NS |
| Tregs, cells/μL | 20.2 (0.5-74.3) | 29.4 (7.5-122.9) | 38.4 (8-104) | < 0.0001 |
Table 5 Changes in T lymphocyte subpopulations at T0, T3, and T6 time points in patients with panel reactive antibodies (+)
| Parameter | T0 | T3 | T6 | P value |
| Lymphocyte, % | 17.8 (11.2-40) | 16.4 (7.5-36.8) | 20.9 (12.2-36.4) | 0.07 |
| Lymphocyte, cells/μL | 1100 (700-2600) | 1300 (700-3600) | 1700 (525-3200) | 0.009 |
| CD4+, % | 41.5 (25.3-59.5) | 42.3 (29.2-65.3) | 46.5 (27.4-62) | NS |
| CD4+, cells/μL | 435 (253-1362.4) | 548.9 (292-1371.3) | 744 (220-1888) | 0.008 |
| CD8+, % | 23.4 (10.5-53.1) | 27.4 (10.3-53.6) | 29.9 (11.6-56.2) | 0.005 |
| CD8+, cells/μL | 294.9 (91.7-665.6) | 408 (123.6-1234.8) | 504.9 (114.4-955.4) | < 0.0001 |
| CD4CD28null, % | 7.2 (0-32.1) | 5.3 (0.2-24.8) | 4 (0.1-28.6) | NS |
| CD4CD28null, cells/μL | 27.3 (0-206) | 22.8 (1.5-234) | 24.2 (1.3-244) | NS |
| CD8CD28null, % | 48.4 (15.1-91.5) | 47.1 (10.7-82.1) | 36.5 (7.7-82) | NS |
| CD8CD28null, cells/μL | 122.2 (13-583) | 200 (19-547) | 160 (22-726) | NS |
| CD16/56, % | 18.4 (4.4-34.2) | 11.4 (2.9-26) | 7.9 (3-24.6) | < 0.0001 |
| CD16/56, cells/μL | 190.4 (94.8-393.6) | 157.5 (34.8-450) | 135.7 (23.76-385.7) | 0.07 |
| Tregs, %, on CD4 | 4.2 (1.5-7.3) | 3.3 (1.2-6.8) | 4.4 (1.4-8.6) | NS |
| Tregs, cells/μL | 18.9 (5.8-73.5) | 20.9 (7.4-65.8) | 26.7 (8.5-103.8) | NS |
- Citation: Vagiotas L, Stangou M, Kasimatis E, Xochelli A, Myserlis G, Lioulios G, Nikolaidou V, Panteli M, Ouranos K, Antoniadis N, Maria D, Papagianni A, Tsoulfas G, Fylaktou A. Effect of panel reactive antibodies on T cell immunity reinstatement following renal transplantation. World J Transplant 2022; 12(10): 313-324
- URL: https://www.wjgnet.com/2220-3230/full/v12/i10/313.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i10.313